New Data Shows TAGRISSO ® Significantly Reduces Disease Progression in EGFR-Mutated Lung Cancer Patients
Sunday, 2 June 2024, 15:44
LAURA Phase III Trial Results
The LAURA Phase III trial reported that TAGRISSO ® demonstrated a remarkable 84% reduction in the risk of disease progression or death in patients with unresectable, Stage III EGFR-mutated lung cancer when compared to a placebo.
Breakthrough Treatment
This significant outcome underscores the efficacy of TAGRISSO ® in improving survival rates and disease management for patients in this specific population.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.